The Buy rating and maintained price target by Mizuho analyst Uy Ear indicate a positive outlook for Arcutis Biotherapeutics. This reaffirmation of the Buy rating is likely to have a positive short-term impact on the stock price, as it signals confidence in the company's prospects.